Gilead Sciences, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Gilead Sciences, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Gilead Sciences, Inc. - Product Pipeline Review - 2015', provides an overview of the Gilead Sciences, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Gilead Sciences, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Gilead Sciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Gilead Sciences, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Gilead Sciences, Inc.'s pipeline products

Reason to Buy

- Evaluate Gilead Sciences, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Gilead Sciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Gilead Sciences, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Gilead Sciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Gilead Sciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Gilead Sciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Gilead Sciences, Inc. Snapshot 6
Gilead Sciences, Inc. Overview 6
Key Information 6
Key Facts 6
Gilead Sciences, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Gilead Sciences, Inc. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 18
Gilead Sciences, Inc. - Pipeline Products Glance 20
Gilead Sciences, Inc. - Late Stage Pipeline Products 20
Gilead Sciences, Inc. - Clinical Stage Pipeline Products 22
Gilead Sciences, Inc. - Early Stage Pipeline Products 25
Gilead Sciences, Inc. - Drug Profiles 27
(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide) 27
(emtricitabine + tenofovir alafenamide) 29
(ledipasvir + sofosbuvir) 30
(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide) 33
(sofosbuvir + GS-5816) 34
ambrisentan 36
GS-6615 38
idelalisib 39
momelotinib dihydrochloride 42
ranolazine ER 45
tenofovir alafenamide 47
(GS-9857 + GS-5816 + sofosbuvir) 49
(ranolazine hydrochloride + dronedarone hydrochloride) 50
acalisib 51
GS-4774 52
GS-4997 53
GS-5745 54
GS-9256 55
GS-9620 56
GS-9669 58
GS-9973 59
ONO-4059 60
presatovir 62
Px-102 63
Px-104 64
regadenoson 66
simtuzumab 68
vedroprevir 70
GS-5829 71
GS-6637 72
GS-9857 73
GS-9883 74
GS-9901 75
velpatasvir 76
AB-0045 77
GS-548202 78
GS-5759 79
GS-607601 80
GS-8374 81
GS-967 82
Monoclonal Antibodies 1 for Cancer 83
Px-103 84
Small Molecule to Inhibit Histone Deacetylation for Cancer 85
Small Molecule to Inhibit Histone Methyltransferase for Cancer 86
GS-563253 87
GS-599220 88
Monoclonal Antibody for HIV / AIDS 89
Small Molecule to Inhibit NS4B Protein for HCV 90
Small Molecules to Inhibit NS3 Protease for Hepatitis C 91
Gilead Sciences, Inc. - Pipeline Analysis 92
Gilead Sciences, Inc. - Pipeline Products by Target 92
Gilead Sciences, Inc. - Pipeline Products by Route of Administration 94
Gilead Sciences, Inc. - Pipeline Products by Molecule Type 95
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action 96
Gilead Sciences, Inc. - Recent Pipeline Updates 98
Gilead Sciences, Inc. - Dormant Projects 122
Gilead Sciences, Inc. - Discontinued Pipeline Products 123
Discontinued Pipeline Product Profiles 123
Gilead Sciences, Inc. - Company Statement 127
Gilead Sciences, Inc. - Locations And Subsidiaries 132
Head Office 132
Other Locations & Subsidiaries 132
Appendix 138
Methodology 138
Coverage 138
Secondary Research 138
Primary Research 138
Expert Panel Validation 138
Contact Us 138
Disclaimer 139

List of Tables

Gilead Sciences, Inc., Key Information 9
Gilead Sciences, Inc., Key Facts 9
Gilead Sciences, Inc. - Pipeline by Indication, 2015 12
Gilead Sciences, Inc. - Pipeline by Stage of Development, 2015 16
Gilead Sciences, Inc. - Monotherapy Products in Pipeline, 2015 17
Gilead Sciences, Inc. - Combination Treatment Modalities in Pipeline, 2015 18
Gilead Sciences, Inc. - Partnered Products in Pipeline, 2015 19
Gilead Sciences, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 20
Gilead Sciences, Inc. - Out-Licensed Products in Pipeline, 2015 21
Gilead Sciences, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 22
Gilead Sciences, Inc. - Pre-Registration, 2015 23
Gilead Sciences, Inc. - Phase III, 2015 24
Gilead Sciences, Inc. - Phase II, 2015 25
Gilead Sciences, Inc. - Phase I, 2015 27
Gilead Sciences, Inc. - Preclinical, 2015 28
Gilead Sciences, Inc. - Discovery, 2015 29
Gilead Sciences, Inc. - Pipeline by Target, 2015 95
Gilead Sciences, Inc. - Pipeline by Route of Administration, 2015 97
Gilead Sciences, Inc. - Pipeline by Molecule Type, 2015 98
Gilead Sciences, Inc. - Pipeline Products by Mechanism of Action, 2015 99
Gilead Sciences, Inc. - Recent Pipeline Updates, 2015 101
Gilead Sciences, Inc. - Dormant Developmental Projects,2015 125
Gilead Sciences, Inc. - Discontinued Pipeline Products, 2015 126
Gilead Sciences, Inc., Other Locations 135
Gilead Sciences, Inc., Subsidiaries 136